Home' Australian Pharmacist : Australian Pharmacist July 2015 Contents Australian Pharmacist July 2015 I © Pharmaceutical Society of Australia Ltd.
Make the switch
to MAXIGESIC® for
codeine-free pain relief
For double action pain relief
without codeine – make the switch
MAXIGESIC® is clinically proven in dental
studies to reduce pain levels by at least
32% more than a full daily OTC dose of
either Paracetamol or Ibuprofen alone.
In addition, MAXIGESIC® is the only
combination analgesic that delivers the
maximum recommended daily OTC dose
of 4000mg paracetamol and 1200mg
ibuprofen, if required*.
MAXIGESIC® provides double action
relief from a wide range of pain –
without codeine. Review the Product
Information at www.maxigesic.com.au
*2 tablets of MAXIGESIC® taken every
6 hours over a 24 hour period.
1. Merry, A. F., Gibbs, R. D., Edwards, J., Ting, G. S., Frampton,
C., Davies, E. and Anderson, B. J. (2010). “Combined
acetaminophen and ibuprofen for pain relief after oral
surgery in adults: a randomized controlled trial” British
Journal of Anaesthesia 104(1): 80-88 . Result achieved
in a trial of post-operative pain relief after removal of
1–4 wisdom teeth using Maxigesic® compared with
Paracetamol 4000mg or Ibuprofen 1200mg alone per day
in four divided doses.
Australians with metastatic bowel
cancer have been recognised in an
expanded PBS listing for Erbitux
(cetuximab). Since 1 June Erbitux has
been reimbursed as a first line therapy
for patients with epidermal growth
factor receptor (EGFR)-expressing, RAS
wild-type metastatic colorectal cancer
(mCRC). Erbitux is presently the only
EGFR-antibody to be PBS reimbursed
as a first line treatment for mCRC
The CRYSTAL study was a
randomised, Phase III study involving
1,198 chemo-naïve patients with
EGFR-expressing mCRC in Stage IV,
of whom 666 had confirmed KRAS
wild-type (exon 2) tumours.
The study showed that progression-free
survival, overall survival time and
response rate were significantly better in
patients with KRAS wild-type mCRC who
received Erbitux plus FOLFIRI, compared
with FOLFIRI alone. The updated
RAS analyses further increased
The Phase III study FIRE-3 involved
592 patients and showed an 8.1 month
increase in median overall survival
to 33.1 months when using first
line Erbitux plus Folfiri compared to
using bevacizumab plus Folfiri in
RAS wild-type mCRC. (Pre-planned,
retrospective analyses of the secondary
endpoint (OS); the primary endpoint
(ORR) was not met.)3,4
1. Van Custem E, et al. J Clin Oncol 2011;29: 2011–19
2. Ciardiello, et al., ASCO 2014, Abstract No. 3506.
3. Heinemann, et al. Lancet Oncol 2014;15:1065–1075.
4. Stintzing, et al. ESMO 2014, Abstract No. LBA11.
A new cancer medicine, Imbruvica
(ibrutinib) that works to prevent
leukaemia cells from multiplying and
spreading1 has been approved by the
Therapeutic Goods Administration
(TGA), for the treatment of patients with
Chronic Lymphocytic Leukaemia (CLL)
where their disease has progressed
despite treatment with other standard
According to Janssen it will
change the way the most common form
of leukaemia is treated.
Imbruvica is the first of a new form of
highly targeted therapies called Bruton’s
Tyrosine Kinase inhibitors. Taken as daily
capsules, the therapy works by blocking
signals to the protein that stimulates
leukaemia cells to multiply and spread.
It is generally well-tolerated, with the
most common side-effects seen in CLL
patients in clinical trials being diarrhoea,
muscle and joint pain, nausea, fatigue,
bruising, fever, constipation, skin rashes,
upper respiratory tract infections, low
white blood cell counts and anaemia.
Imbruvica is contraindicated in patients
who have known hypersensitivity to
ibrutinib or its excipients. The use of
preparations containing St. John’s Wort
Warfarin or other vitamin K antagonists
should not be administered concomitantly
with ibrutinib. Fish oil and vitamin E
preparations should be avoided.
1. Janssen-Cilag Pty Ltd Australia. IMBRUVICA Approved
Product Information. 20 April 2015
2. NCCN Guide on CLL to Shift Toward Targeted Therapies
Medscape. Mar 16, 2015.
3. Parmar S, et al. Ibrutinib (Imbruvica): A Novel Targeted
Therapy for Chronic Lymphocytic Leukemia P T. 2014 Jul;
39(7): 483-487, 519.
4. Badar T, et al. Ibrutinib: a paradigm shift in management
of CLL. Expert Rev Hematol. 2014 Dec;7(6):705-17 . doi:
Links Archive Australian Pharmacist June 2015 Australian Pharmacist August 2015 Navigation Previous Page Next Page